Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(7 months ago) | |
US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 29 days ago) | |
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 29 days ago) | |
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(a month ago) | |
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
US9649311 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(6 years from now) | |
US9649311 (Pediatric) | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(6 years from now) | |
US10772888 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(7 years from now) |
Isentress Hd is owned by Msd Sub Merck.
Isentress Hd contains Raltegravir Potassium.
Isentress Hd has a total of 12 drug patents out of which 6 drug patents have expired.
Expired drug patents of Isentress Hd are:
Isentress Hd was authorised for market use on 12 October, 2007.
Isentress Hd is available in tablet;oral dosage forms.
Isentress Hd can be used as treatment of hiv infection, integrase inhibition for the treatment of hiv infection, treatment of hiv-1 infection.
Drug patent challenges can be filed against Isentress Hd from 22 May, 2020.
The generics of Isentress Hd are possible to be released after 30 March, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Strength(NS) | May 26, 2020 |
New Dosing Schedule(D-167) | May 26, 2020 |
New Patient Population(NPP) | Dec 21, 2014 |
Pediatric Exclusivity(PED) | May 22, 2021 |
M(M-114) | Mar 28, 2015 |
New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection
Dosage: TABLET;ORAL